Caring for someone with this diagnosis? Eleplan keeps diagnoses, medications, documents and every specialist in one plan.
Start free with EleplanCancer-associated retinopathy
ORPHA:71505Disease
Also called CAR syndrome · Paraneoplastic retinopathy
What it is
A rare paraneoplastic disease of the eye characterized by the presence of extraocular malignancy and circulating autoantibodies against retinal proteins.
Key facts
- Age of onset
- Adult
- Inheritance
- Not applicable
- Classified as
- Disease
Signs and symptoms
Common30–79%
13- Adult-onset night blindness
- Anti-recoverin antibody positivity
- Autoimmune antibody positivity
- Electronegative electroretinogram
- Female reproductive system neoplasm
- Malignant genitourinary tract tumor
- Neoplasm of the breast
- Photophobia
- Photopsia
- Progressive visual field defects
- Reduced visual acuity
- Small cell lung carcinoma
- Visual loss
These ranges are how often a sign appears across everyone diagnosed, not a prediction for one person — most people have some of these and not others. Orphanet also records findings that are specifically absent in this disease; those are in the data but not listed here.
ICD-10 codes
ICD-10 has no distinct code for most rare diseases, so many are filed under the nearest available one. A shared code identifies the group, not this disease — the ORPHAcode above is what identifies it.
Related health topics
Reached through the ICD-10 categories this disease is filed under, so these describe the broader group rather than this disease specifically.
Cross-references
Orphadata Science: Free access data from Orphanet. © INSERM 1999. Data version 2026-06-23. Available under CC BY 4.0. This is a reference, not medical advice.
Powered by Eleplan
A rare diagnosis is just the start. Eleplan keeps the whole care plan in one place.
Diagnoses, medications, documents, appointments, and the whole care team — organized and always in sync, so you are not retelling the same story to every new specialist. With Ellie, your AI care assistant, on top of it. Free to start.